Aerovate Therapeutics (Aerovate Therapeutics) Net Current Asset Value : $3.13 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Aerovate Therapeutics Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Aerovate Therapeutics's net current asset value per share for the quarter that ended in Mar. 2024 was $3.13.

The historical rank and industry rank for Aerovate Therapeutics's Net Current Asset Value or its related term are showing as below:

AVTE' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.68 Med: 3.06 Max: 9.45
Current: 6.44

During the past 5 years, the highest Price-to-Net-Current-Asset-Value Ratio of Aerovate Therapeutics was 9.45. The lowest was 1.68. And the median was 3.06.

AVTE's Price-to-Net-Current-Asset-Value is ranked worse than
66.47% of 1041 companies
in the Biotechnology industry
Industry Median: 3.95 vs AVTE: 6.44

Aerovate Therapeutics Net Current Asset Value Historical Data

The historical data trend for Aerovate Therapeutics's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aerovate Therapeutics Net Current Asset Value Chart

Aerovate Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Net Current Asset Value

-1.53

-0.62

7.02

4.97

3.83

Aerovate Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Current Asset Value	Get a 7-Day Free Trial													4.40	5.02	4.43	3.83	3.13

Competitive Comparison of Aerovate Therapeutics's Net Current Asset Value

For the Biotechnology subindustry, Aerovate Therapeutics's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aerovate Therapeutics's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aerovate Therapeutics's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Aerovate Therapeutics's Price-to-Net-Current-Asset-Value falls into.

Aerovate Therapeutics Net Current Asset Value Calculation

Aerovate Therapeutics's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2023 is calculated as

	Net Current Asset Value Per Share		(A: Dec. 2023 )
=	(Total Current Assets	-	Total Liabilities	-	Minority Interest	-	Preferred Stock)	/	Shares Outstanding (EOP)
=	(124.232	-	17.962	-	0	-	0)	/	27.7627
=	3.83

Aerovate Therapeutics's Net Current Asset Value (NCAV) per share for the quarter that ended in Mar. 2024 is calculated as

	Net Current Asset Value Per Share		(Q: Mar. 2024 )
=	(Total Current Assets	-	Total Liabilities	-	Minority Interest	-	Preferred Stock)	/	Shares Outstanding (EOP)
=	(103.239	-	15.917	-	0	-	0)	/	27.8988
=	3.13

Aerovate Therapeutics (NAS:AVTE) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.

Aerovate Therapeutics Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Aerovate Therapeutics's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Aerovate Therapeutics (Aerovate Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aerovate Therapeutics Inc (NAS:AVTE) » Definitions » Net Current Asset Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

930 Winter Street, Suite M-500, Waltham, MA, USA, 02451

Website

https://www.aerovatetx.com

Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, a devastating disease impacting people in the United States and Europe.

Executives

Hunter Gillies	officer: Chief Medical Officer	C/O AEROVATE THERAPEUTICS, INC., 200 BERKELEY STREET, FLOOR 18, BOSTON MA 02116
Ralph Niven	officer: Chief Development Officer	C/O AEROVATE THERAPEUTICS, INC., 200 BERKELEY STREET, FLOOR 18, BOSTON MA 02116
Benjamin T Dake	officer: See Remarks	C/O AEROVATE THERAPEUTICS, INC., 200 BERKELEY STREET, FLOOR 18, BOSTON MA 02116
Marinus Verwijs	officer: SENIOR VICE PRESIDENT, CMC	C/O AEROVATE THERAPEUTICS, INC., 200 BERKELEY STREET, FLOOR 18, BOSTON MA 02116
Timothy P Noyes	director, officer: Chief Executive Officer	1365 MAIN STREET, WALTHAM MA 02451
Habib J Dable	director	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Timothy Pigot	officer: Chief Commercial Officer	AEROVATE THERAPEUTICS, INC., 930 WINTER STREET, SUITE M-500, WALTHAM MA 02451
Donald J Santel	director	4362 24TH STREET, SAN FRANCISCO CA 94114
George A Eldridge	officer: See Remarks	C/O TARGANTA THERAPEUTICS CORPORATION, 222 THIRD STREET SUITE 2300, CAMBRIDGE MA 02142
Allison Dorval	director	C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Maha Katabi	director, 10 percent owner	SOFINNOVA INVESTMENTS, 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116